Delirium is a common and serious condition experienced by many older adults during and after hospital stays. It can manifest as sudden confusion, altered awareness, agitation, and emotional disturbance. The condition not only causes distress for patients and families but also leads to longer hospital stays, higher health care costs, and worse long term outcomes. In recent years clinicians and researchers have urgently sought safer ways to manage delirium related symptoms in older adults after they leave the hospital.
A new nationwide cohort study using advanced analytical methods offers fresh insight into how one medication, trazodone, compares to commonly used atypical antipsychotics when prescribed for delirium management in adults aged 65 and older. This study shows promising safety outcomes associated with trazodone when compared to atypical antipsychotic drugs such as quetiapine, risperidone, and olanzapine after hospital discharge with a diagnosis of delirium.
In this article we will walk through the background, key findings, clinical meaning, practical implications, and limitations of this study to help clinicians, caregivers, and health systems interpret what the evidence means for real world care.
Delirium is a serious form of acute brain dysfunction that affects a large proportion of hospitalized older adults. It has multiple causes including infection, pain, medications, sensory overload, and metabolic imbalance. Its onset may be sudden and its course unpredictable. Up to 50 percent of older adults discharged from the hospital after delirium continue to have symptoms that affect their daily function.
Guidelines recommend prioritizing non drug based interventions such as environmental supports, orientation strategies, sleep promotion, hydration, and mobilization. Pharmacological treatments are only advised when symptoms pose a risk to patient safety or cause serious distress and non drug strategies have not worked.
Traditionally antipsychotic drugs have been used for agitation and psychosis related to delirium. While effective in some cases they carry significant risks in older adults including falls, sedation, cognitive worsening, pneumonia, heart rhythm problems, urinary complications, and even death.
Trazodone is an antidepressant that at low doses has sedating effects. Clinicians have increasingly prescribed it as an alternative when antipsychotics are considered too risky. Until now there has been limited evidence directly comparing outcomes of trazodone versus atypical antipsychotics in older adults recovering from delirium episodes.
To understand which medication is safer, researchers conducted a target trial emulation cohort study. This method uses real world data and advanced statistical techniques to mimic what a randomized controlled trial might show while accounting for differences in patient characteristics. Two nationwide US data sources were analyzed:
Adults aged 65 years or older who were newly prescribed either trazodone or an atypical antipsychotic (quetiapine, risperidone, or olanzapine) within 30 days of discharge after a hospital stay with a delirium diagnosis were included. A comprehensive list of 162 baseline factors such as age, comorbidities, prior health care use, frailty, and dementia status was balanced between groups using propensity score weighting.
The primary outcome was rehospitalisation from any cause. Secondary outcomes included reasons for rehospitalization such as delirium, falls, pneumonia, urinary tract infection, stroke, and all cause mortality.
Around 11 678 adults received trazodone and 29 590 received atypical antipsychotics in the pooled analysis. Median follow up was approximately 58 days. The key results were as follows:
This study provides evidence that when pharmacological treatment is considered necessary for managing delirium related behavioural symptoms after hospital discharge, trazodone may be a safer alternative to atypical antipsychotics in many older adult populations.
The researchers offer several plausible explanations:
The lower risk of all cause mortality is especially notable given previous studies showing increased death risk with antipsychotic use in older adults. These findings align with prior long term care research that also showed lower mortality with trazodone versus antipsychotics.
While this evidence points toward potential advantages of trazodone, it does not mean trazodone should replace non drug delirium interventions or be used indiscriminately. Non pharmacological care remains the cornerstone of delirium management.
Trazodone may be considered:
Clinicians should still evaluate each patient individually, especially those aged 80 years and older where the benefit was less clear.
Every study has limitations and this one is no exception. Important points include:
Despite these limitations the findings are robust, consistent across sensitivity analyses, and are supported by plausible biological mechanisms and previous research.
This large nationwide cohort study suggests that in older adults aged 65 years and older who are discharged from hospital after a delirium episode, prescribing trazodone is associated with lower risks of rehospitalisation and death compared to atypical antipsychotic medications.
These results support considering trazodone as a safer pharmacological option when non drug interventions are insufficient and symptoms require treatment. However, clinicians should continue prioritizing first line delirium care strategies while weighing the risks and benefits in each older adult patient.
The study provides meaningful evidence to inform clinical decision making and may influence how delirium related symptoms are managed after hospital discharge.
Yang CT, Wilkins JM, Pritchard KT, Chen Q, Liu X, Kim DH, et al. Safety outcomes of trazodone versus antipsychotics for delirium after hospital admission in adults aged 65 years and older a nationwide cohort study using a target trial emulation framework. The Lancet Healthy Longevity Volume 6, Issue 12, December 2025. Open access article.
This blog is intended for educational and informational purposes only and does not constitute medical advice. Clinical decisions should always be made in consultation with qualified health care professionals familiar with individual patient needs. The content reflects findings from a population based observational study and should not replace clinical judgment or individualized patient care.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.